How to Treat SIBO: An Evidence-Based, Step-by-Step Guide

Small intestinal bacterial overgrowth (SIBO) means too many microbes crowd the upper gut. It brings bloating, gas, and shifting bowel habits. Effective care pairs a targeted drug like rifaximin with steps that fix the root cause. The overgrowth comes back in about 44% of people within nine months (Lauritano 2008).

SIBO stands for small intestinal bacterial overgrowth. Too many microbes settle where few belong. They ferment food early in the digestive system. That disrupts digestion and blocks nutrient absorption.

Normally, most bacteria live down in the colon, the large intestine. In SIBO they crowd higher in the intestine. There they ferment carbohydrates and produce gas in large amounts.

The subtype pattern shapes your care. One form runs on hydrogen gas. Another comes from archaea that make methane. Doctors now call that intestinal methanogen overgrowth (IMO), since archaea are not bacteria. A third form, hydrogen sulfide (H2S), is also recognized.

SIBO overlaps heavily with irritable bowel syndrome (IBS). Many people with an IBS label share the same drivers. A standard IBS workup often misses these overlapping conditions.

Symptoms are mostly digestive. Complaints run from diarrhea to constipation.

Typical signs include:

• Bloating and a swollen belly
• Excess gas and belching
• Diarrhea, constipation, or an alternating pattern
• Abdominal pain and general discomfort
• Poor nutrient absorption, sometimes with low vitamins such as B12
• Fatigue that tracks with malabsorption

Methane-driven IMO leans toward constipation. Looser stools point the other way. These overlaps mean symptoms cannot confirm the condition alone. The Cleveland Clinic lists the same complaints among typical signs.

Some clinicians also order a stool workup. It can flag inflammation and a wider microbial imbalance. Fatigue and brain fog sometimes follow the malabsorption behind these conditions.

Diagnosis usually relies on breath testing. You drink a sugar substrate such as glucose or lactulose. The analysis then gauges the gases you exhale.

IFDW's at-home breath screen relies on glucose. It collects 9 samples every 20 minutes across 3 hours. You follow the test instructions. Results land within 24 to 72 hours.

Breath screening has real limits. Eamonn Quigley at Houston Methodist warned in 2025 against reflexively prescribing the drug on shaky results. A 2024 review by Kashyap and colleagues also questioned reliability.

The most useful first move is knowing your subtype. An initial screen tells you which subtype you face.

A sound protocol follows a simple loop:

1. Screen to confirm the excess and name the subtype behind your complaints.
2. Treat with the approach matched to that subtype.
3. Retest a few weeks later to confirm the microbes are gone and pick a next round or a prevention phase.

No single approach fits everyone. Your subtype, budget, complaints, and root cause all steer the choice.

This table maps each subtype to a starting option. Use it with your clinician to shape the best plan for you.

SubtypeCommon starting optionFood nuanceH2-dominant SIBORifaximin aloneLow-FODMAP may ease symptomsMethane / IMORifaximin plus neomycinStandard fermentable-carb curbs can worsen constipationH2S typeEmerging, less definedDiscuss with a clinician

Antibiotics are the conventional first line in the ACG's 2020 guideline. One gut-selective drug is best studied. The guideline rates most recommendations as low-certainty evidence. So this is a reasonable start, not a promise. The drug is well tolerated, though side effects can occur.

Experts also caution against reaching for antibiotics in every case. Quigley urges a confirmed diagnosis before that step.

This drug is non-absorbed and gut-selective. It works inside the gut against overgrowing microbes. The initial course is usually 550 mg three times a day for 14 days.

The ACG 2020 guideline cites roughly 61 to 78% breath normalization for rifaximin. A 2017 meta-analysis pooled eradication near 71%. These trials measure breath results, not a lasting cure.

Methane comes from archaea, mainly Methanobrevibacter smithii. These organisms shrug off that drug on their own.

So methane care means combination therapy. A typical regimen adds neomycin 500 mg to rifaximin 550 mg for about 14 days. Metronidazole is another second-agent option.

Pimentel's 2010 work at Cedars-Sinai found that a combination of two agents beat either one alone. The archaea also reach past the gut into the colon, which helps explain why methane can be stubborn.

This third type is named but thinly studied. Options include bismuth and lower sulfur intake, best explored with a professional.

Xifaxan, the brand drug, is not FDA-approved for this use. So it is off-label, and insurers often deny coverage.

Out of pocket, a 14-day course can run about $2,000 to $2,600. Discount cards and maker help can lower the bill.

A natural plan leans on botanical antimicrobials, an elemental formula, and food change.

Many people want a natural route without prescriptions. Botanicals can help. They still work best inside a confirmed, monitored plan.

Plant-based antimicrobials are the most-studied natural answer. Common agents are berberine, oregano oil, allicin from garlic, and neem.

The herbal evidence is thin. The best-known trial came from Johns Hopkins in 2014. Chedid and colleagues compared these agents against the drug in 104 patients.

Response meant a negative follow-up breath result. It reached about 46% with botanicals versus 34% with the drug. The gap was not significant (P=.24).

Among non-responders, 8 of 14 turned breath-negative after a botanical rescue. The trial was limited and not randomized. So berberine, oregano oil, allicin, and neem are worth discussing, not a proven equal to the drug.

• Effectiveness: the drug about 61 to 78% (ACG 2020); botanicals about 46% versus 34% in one limited 2014 study, not significant.
• Evidence quality: the drug has guideline support at low certainty; herbal evidence stays limited.
• Cost: off-label Xifaxan often $2,000 to $2,600 per course; plant products vary and are not FDA-regulated.
• Side effects: antibiotic agents can disturb the wider microbiome; botanicals can cause reflux or loose stools.
• Recurrence: both share one weakness. Neither fixes the root cause alone.

A SIBO diet is a strong adjunct. It manages symptoms. It does not eradicate the overgrowth.

Cutting fermentable carbohydrates eases pressure and cramping. Pain often settles too. Starving the microbes does not clear them.

One caution comes from Mark Pimentel at Cedars-Sinai. Do not hold a strict eating plan during antibiotic care. The bacteria must stay active to be killed.

This is the best-studied eating plan. Symptom relief lands around 50 to 70% in irritable bowel syndrome (IBS) and SIBO overlap data.

It runs in three phases. Strict elimination lasts 2 to 6 weeks. Reintroduction adds foods back one at a time. A personalized pattern follows.

Monash University developed the method. Its team is clear this is not a lifetime plan. Long-term limits starve helpful fibers and prebiotics.

So low-FODMAP belongs under a dietitian's care. Prebiotics feed a healthy microbiome and matter for balance.

An elemental reset runs two to three weeks for a stubborn case.

In Pimentel's 2004 study, the lactulose breath result normalized in about 80% of people after two weeks.

A 2025 Cedars-Sinai study by Ali Rezaie tried a palatable formula in 30 adults. Breath results normalized in 73%. Symptoms improved in 83%. Everyone finished the course.

Average weight loss was about 3.5 kg. So the elemental formula is a supervised medical step, not a casual food plan.

Standard fermentable-carb limits can worsen methane-driven slowdown.

Meal spacing of about 4 to 5 hours helps motility. Even trace amounts of food can stall the cleanup between meals. This reflects expert consensus, not trial proof.

An anti-inflammatory diet is sometimes suggested. It may calm inflammation and discomfort, but it is not a proven cure. Any anti-inflammatory eating pattern works alongside treatment, not instead of it.

Prokinetics stimulate the migrating motor complex (MMC). The MMC is the cleansing wave that sweeps microbes out of the digestive system between meals. A sluggish migrating motor complex drives regrowth and relapse.

Doctors sometimes add off-label medications. These include low-dose naltrexone, prucalopride, and low-dose erythromycin.

Such agents often continue for 3 to 6 months after the kill phase. They are largely mechanistic. Evidence for relapse prevention is thin, so treat them as plausible support, not proven therapy.

Some people add supplements for general gut support. Probiotics are genuinely debated.

So discuss probiotics with your clinician rather than assume benefit. The same caution applies to any products sold as a cure.

Recurrence is common. The bacteria usually flag an underlying predisposition. A healthy microbiome depends on a steadier gut, not on repeated kill rounds.

In Lauritano's 2008 study, it returned in 12.6% at 3 months, 27.5% at 6 months, and 43.7% by 9 months. Without root-cause work, the microbes return.

Clearing bacteria without fixing the cause invites relapse. So prevention and long-term care weigh as much as the kill phase.

• Treat the root cause: impaired motility, structural problems, low stomach acid, or medications such as chronic PPIs and opioids.
• Support the MMC: steady meal spacing and, when fitting, a prokinetic for 3 to 6 months.
• Manage stress and sleep: the vagus nerve helps steer motility, so stress reduction, sleep, and movement all help.
• Finish your eating program by moving into reintroduction instead of staying stuck in elimination.
• Retest after care to confirm the microbes are gone.

Once SIBO clears, the prevention phase decides whether results last. If symptoms return despite good habits, a clinician should hunt for a structural or motility cause.

Timelines vary. A typical arc runs like this:

• Weeks 1 to 2: the antimicrobial course, with some die-off and early relief both possible.
• Weeks 2 to 4: shift toward supportive eating and add motility help.
• Weeks 4 to 6: retest to check the result and decide next steps.
• Beyond: reintroduce foods and continue prevention for months.

Many people notice easing within two weeks. Once SIBO is controlled, the prevention window stretches over months.

There is no single finish line. Breath normalization is not the same as a permanent cure.

For many people, SIBO is a condition to manage over time rather than beat in one round. Many patients feel better before breath results fully normalize. In practice, lasting progress comes from treating the underlying driver and steadying digestion. Confirm it by retesting.

Some signs call for prompt care. See a clinician if you notice:

• Unintended weight loss
• Anemia or low vitamins such as B12
• Ongoing malabsorption of nutrients
• Symptoms that resist usual care
• A history of abdominal surgery or structural bowel disease

Expert opinion warns against prescriptions for everyone. A confirmed diagnosis and attention to causes matter more than reflexive care. Celiac disease and other structural drivers deserve their own workup.

Several approaches circulate online but are not established care. A lovastatin lactone (SYN-010) targets methanogens. Yet no statin is FDA-approved for either type as of 2026.

Fecal microbiota transplantation stays investigational, with feasibility trials still recruiting. The appeal is restoring microbial balance instead of killing bacteria.

Biofilm agents rest on thin studies. Try them only under expert review.

There is no overnight fix. Confirm the result, run a 14-day antibiotic course, then retest with expert guidance.

It is often managed, not cured in one round. It returned in about 44% of people within nine months in the 2008 data.

Botanicals, an elemental formula, and food changes help some people under supervision. Food controls symptoms rather than clearing the excess microbes.

Yes. Methane archaea resist that drug alone, so IMO is commonly treated with two drugs together for 14 days.

Off-label coverage is often denied, so a 14-day brand course can run about $2,000 to $2,600. IFDW's at-home breath screen is $209.00 USD, or $299.00 USD with an expert review video.

The right approach depends on your subtype.

IFDW's at-home SIBO Breath Test ($209.00 USD) confirms your gas type before care. It also lets you verify success by retest. It is available in all 50 states, and no prescription is required. You can also book a free 15-minute expert call for next steps.

This article is for educational purposes only and does not replace medical advice from a licensed healthcare professional. It draws on research and experience and should not substitute for professional diagnosis or treatment. The strategies here may not suit everyone. Please consult a healthcare professional before starting any care.

• Pimentel M, et al. ACG Clinical Guideline on SIBO. Am J Gastroenterol. 2020.
• Lauritano EC, et al. SIBO relapse following antimicrobial therapy. Am J Gastroenterol. 2008.
• Chedid V, et al. Botanical therapy compared with antimicrobials for SIBO. Glob Adv Health Med. 2014.
• Pimentel M, et al. A 14-day elemental formula and breath normalization. Dig Dis Sci. 2004.
• Rezaie A, et al. Palatable elemental formula for SIBO and IMO. Clin Gastroenterol Hepatol. 2025.
• Quigley EMM. Re-examining SIBO. Houston Methodist, 2025.